8-K: uniQure Q2 2026 Results: AMT-130 Submission on Track, Cash Runway Extended

uniQure reports strong Q2 2026 results with key regulatory milestones for AMT-130, a strengthened financial position extending cash runway to 2030, and positive early data for AMT-260.

Summary

• uniQure announced its second quarter 2026 financial results and provided a corporate update.
• The company remains on track to submit a Biologics License Application (BLA) for AMT-130 for Huntington's disease in the third quarter of 2026, following alignment with the FDA on an accelerated approval pathway.
• Topline four-year data from the Phase I/II study of AMT-130 are expected in September 2026.
• Preliminary data from the first cohort of the AMT-260 Phase I/IIa trial for refractory mesial temporal lobe epilepsy showed early biological signals and a favorable safety profile.
• The company strengthened its financial position through a $259 million follow-on offering, extending its cash runway into 2030.
• Revenue for Q2 2026 was $5.8 million, an increase from $5.3 million in Q2 2025.
• Net loss for Q2 2026 was $81.1 million, or $1.22 per share, compared to a net loss of $37.7 million, or $0.69 per share, in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong progress on key regulatory milestones for AMT-130 and an extended cash runway, despite an increased net loss.

Positives

• U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease are on track for the third quarter of 2026.
• FDA alignment reached for BLA submission of AMT-130 under the accelerated approval pathway.
• Four-year data from the Phase I/II study of AMT-130 are expected in September 2026.
• Preliminary data from the first cohort of AMT-260 showed early biological signals of therapeutic activity and a favorable safety profile.
• Closed an upsized public offering, raising $259 million in gross proceeds.
• Extended cash runway into 2030 with $810.3 million in cash, cash equivalents, and current investment securities as of June 30, 2026.
• Revenue increased to $5.8 million in Q2 2026 from $5.3 million in Q2 2025.
• All 11 dosed patients in the AMT-191 Fabry disease study were withdrawn from ERT.

Negatives

• Net loss for Q2 2026 was $81.1 million, a significant increase from $37.7 million in Q2 2025.
• Basic and diluted loss per ordinary share increased to $1.22 in Q2 2026 from $0.69 in Q2 2025.
• Other expense increased to $8.0 million from $2.2 million, primarily due to increased costs for HEMGENIX supply.
• Other non-operating items, net, resulted in an expense of $27.0 million in Q2 2026, compared to a gain of $6.6 million in Q2 2025, largely due to foreign currency fluctuations and warrant liability changes.
• Dose-limiting toxicities (asymptomatic liver enzyme elevations) were observed in two patients in the mid-dose cohort of the AMT-191 study, requiring immunosuppression.
• Enrollment in the second dose cohort for AMT-260 is expected to be completed in Q3 2026, with updated results in H1 2027, indicating a longer development timeline.

Risks

• The FDA seeks alignment on the confirmatory study design prior to BLA submission for AMT-130, potentially including a randomized standard-of-care control design instead of a sham procedure.
• The confirmatory study for AMT-130 should be well underway, and potentially fully enrolled, at the time of accelerated approval.
• Risks associated with clinical results and the development and timing of programs, including data insufficient for regulatory approval.
• The FDA may conclude that Phase I/II trial data for AMT-130 are not sufficient for BLA or accelerated approval.
• More patient data could lead to a different interpretation than preliminary, interim, or topline data.
• Interactions with regulatory authorities may affect trial initiation, timing, and progress.
• The Company's ability to conduct and fund any required confirmatory study for AMT-130.
• Accelerated approval, if granted, may be subject to difficult or costly post-approval requirements.

Future Outlook

The company expects to submit a BLA for AMT-130 in Q3 2026, with confirmatory study design alignment underway. Topline four-year data for AMT-130 are expected in September 2026. Enrollment for the second dose cohort of AMT-260 is expected in Q3 2026, with updated results in H1 2027. The company anticipates its current cash resources will fund operations into 2030.

Management Comments

• "This has been a defining quarter not just for uniQure, but for the Huntington's disease community," said Matthew Kapusta, chief executive officer at uniQure.
• "Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease."
• "With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it."
• "Beyond AMT-130, we continue to execute across our broader pipeline. With a strong balance sheet, we believe we are well-positioned for what will be a transformative period for uniQure and the patients we serve."

Industry Context

StockSavvy.ai notes that uniQure's progress with AMT-130 for Huntington's disease aligns with the broader industry trend of advancing gene therapies for rare and severe neurological conditions. The company's focus on regulatory milestones and robust data presentation positions it within a competitive landscape where successful clinical development and regulatory approval are paramount for market entry and patient access.

Comparison to Industry Standards

• The BLA submission timeline for AMT-130 under an accelerated approval pathway is a common strategy in the gene therapy sector for addressing unmet medical needs, aiming to bring treatments to market faster.
• The expectation of four-year follow-up data for AMT-130 is significant, as long-term efficacy and safety data are critical benchmarks for gene therapy approvals and market acceptance.
• The preliminary data for AMT-260 showing early biological signals and a favorable safety profile are typical early-stage indicators sought in Phase I/II trials for novel therapies.
• The company's cash runway extending into 2030, supported by a substantial capital raise, is a strong positive, as many biotech companies face funding challenges during extended development cycles.

Stakeholder Impact

• Shareholders: The successful progression of AMT-130 towards potential commercialization and the extended cash runway are positive indicators for future value.
• Patients and Families: Continued progress on AMT-130 for Huntington's disease offers hope for a potential new treatment option.
• Employees: The company's strong financial position and pipeline development support continued investment in its workforce and operations.

Next Steps

• Submit BLA for AMT-130 in the third quarter of 2026.
• Align with the FDA on confirmatory study design for AMT-130 prior to BLA submission.
• Present topline four-year data from the Phase I/II studies of AMT-130 in September 2026.
• Complete enrollment in the second dose cohort in the Phase I/IIa study of AMT-260 in the third quarter of 2026.
• Present updated results from the Phase I/IIa study of AMT-260 in the first half of 2027.
• Initiate the confirmatory study for AMT-130 as expeditiously as possible after FDA alignment.

Key Dates

Recommendation

The company is making significant progress on its lead programs, particularly AMT-130, and has secured a strong financial position. However, the increased net loss, ongoing clinical development risks, and the need for FDA alignment on confirmatory studies warrant a cautious 'hold' rating until further clarity on regulatory pathways and clinical outcomes is achieved.

Keywords

gene therapy, Huntington's disease, AMT-130, AMT-260, AMT-191, clinical trials, regulatory submission, financial results